Tag Archives: adiponectin

Correlation between adiponectin level and obesity as a risk factor for allergy disease

M. Spasovska1*, T. K. Panovska2

1General Hospital, Ohrid, R.Macedonia;
2Faculty of Pharmacy, Ss. Cyril and Methodius University, Skopje, R. Macedonia;
*e-mail: spasovskamilena@yahoo.com

Received: 28 November 2021; Revised: 30 June 2022;
Accepted: 29 September 2022; Available on-line: 06 October 2022

Much research has focused on the connection between two inflammatory conditions, allergic reactions and obesity which has led to a focus on adiponectin, hormone with anti-inflammatory properties secreted by adipose tissue. The aim of this study was to determine the association of adiponectin with obesity, as a risk factor for the development of allergic condition in order to rationalize approach to its treatment. Research methods for inflammatory markers and biochemical parameters involve immunoassay technique. Statistical analysis was performed with Student’s t-test, Wilcoxon T-test and coefficient of correlation. The study included apparently healthy subjects and patients with allergy conditions with confirmed presence of specific IgE, classified into 2 groups according to their body mass index (BMI). The obtained data showed negative correlation (cor = – 0.6), between adiponectin levels and BMI values. Thus, decreased level of adiponectin is associated with increased BMI. The mean values of adiponectin in the studied population, with high statistical differen­ces between the groups (19.1 ± 1.5; 17.7 ± 0.9), (18.8± 1.1; 16.6 ± 1.0) demonstrated the relationship between low adiponectin level and development of obesity, and what, in turn, increasd risk of developing allergic conditions. The assumption was made that adiponectin may be used as a sensitive biochemical marker for early diagnostics of allergic reactions.

Effect of L-carnitine administration on serum insulin and adiponectin levels, and AMPK, APPL1 and PPARγ gene expression in STZ-induced diabetic rat liver

B. Shahouzehi1, K. Barkhordari2, S. Aminizadeh3, Y. Masoumi-Ardakani4*

1Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Iran;
e-mail: bshahouzehi@yahoo.com;
2Department of Virology, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran;
e-mail: khabatzanbil@gmail.com;
3Physiology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Iran;
e-mail: soheilaminizadeh@gmail.com;
4Physiology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Iran;
*e-mail: ymab125@yahoo.com

Diabetes is considered as a metabolic disease in which insulin secretion and functions are disturbed and characterized by hyperglycemia. L-carnitine is synthesized in most mammals and plays critical role in fatty acid oxidation and energy production. Data about the L-carnitine hypoglycemic effects are controversial. We evaluated long-term oral L-carnitine administration effects on blood glucose, insulin and adiponectin levels, as well as expression of AMPK, APPL1 and PPARγ genes in liver of STZ-induced diabetic rats. Group 1 (control), did not receive any treatment, group 2 received 50 mg/kg STZ by i.p injection, group 3 received single dose of 50 mg/kg STZ by i.p injection and also 600 mg/kg/day L-carnitine orally for 5 weeks. Our results showed that L-carnitine long-term oral supplementation significantly reduced blood glucose and normalized insulin levels in diabetic rats. Also, we found that L-carnitine significantly increased AMPK and APPL1 expression, and showed a mild elevation of PPARγ expression. In sum, we suggest that long-term L-carnitine supplementation has beneficial effects on diabetic rats which showed hypoglycemic effects. Probably the beneficial effects of L-carnitine are contributed to the upregulation of insulin sensitizers such as AMPK and adiponectin.